Study shows benefits in obesity-linked conditions of losing more weight with GLP-1 treatment

Study shows benefits in obesity-linked conditions of losing more weight with GLP-1 treatment

New research presented at the European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12–15 May) shows that, following treatment for obesity or diabetes or both, using incretin-based drugs, losing more weight versus less weight, and losing a little weight versus gaining weight, both lead to a relatively lower risk of obesity-related conditions. The study is by Professor John Wilding of the University of Liverpool, UK, and colleagues.